Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB123667 in Moderate or Severe Hepatic Impairment
NCT07559474Phase 1Recruiting
- Sponsor
- Incyte
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of INCB123667 (2 cohorts), sponsored by Incyte. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and 1 more. Started May 2026; status: recruiting.
02
Drugs
INCB123667
Beyond the preview
Go deeper on NCT07559474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559474.